Skip to main content


An infectious disease caused by the SARS-CoV-2 strain of coronavirus that primarily affects the lower respiratory tract

COVID-19 caused more than six million deaths and 600 million cases globally in less than three years. While many people infected with COVID-19 experience only mild symptoms, the disease can have serious ramifications for older people or those with underlying health conditions. In addition, long-COVID and post-COVID symptoms can reduce quality of life for months or even years. As new variants emerge, it is likely that COVID-19 will continue to impact global health, including in communities with high levels of variant-specific vaccination.

For more information about COVID-19, visit:

COVID-19 research at Garvan

The COVID-19 pandemic initiated an unprecedented global research effort. At Garvan, we responded immediately, establishing or collaborating on projects both locally and globally to develop new ways to treat and prevent infection, learn more about virus strains and use our research and expertise to inform global treatment strategies.

Garvan’s excellence in antibody research, immunology, cellular genomics and whole-genome sequencing allows us to make a valuable contribution to the global scientific community’s effort. We are using cutting-edge technology and genomics research to drive innovative projects to prevent and treat COVID-19, with a focus on improving outcomes for patients.